Upadacitinib, sold under the brand name Rinvoq, is a medication used for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and axial spondyloarthritis. Upadacitinib is a selective Janus kinase 1 inhibitor that reduces signaling from multiple proinflammatory cytokines; it is formulated as oral tablets commonly dosed at 15 mg once daily for many indications with higher doses used in specific circumstances per labeling. Pharmacokinetic characteristics include rapid oral absorption with peak plasma concentrations within a few hours, an effective half-life compatible with once-daily dosing, primary metabolism via CYP3A4 with minor CYP2D6 contribution, and elimination through both renal and fecal routes. Clinical use requires baseline infection screening, periodic laboratory monitoring of blood counts, liver enzymes and lipids, and attention to drug interactions with strong CYP3A4 modulators.
Parent: N-Nitroso/ Upadacitinib
Parent: Upadacitinib
Parent: Upadacitinib
Parent: Upadacitinib
Parent: Upadacitinib
Parent: Upadacitinib
Parent: Upadacitinib
Parent: Upadacitinib
Parent: Upadacitinib/ Upadacitinib Hemihydrate
Parent: Upadacitinib
Parent: Upadacitinib
Parent: Upadacitinib
Parent: Upadacitinib
Parent: Upadacitinib
Product quality control and stability testing for upadacitinib follow ICH impurity guidance and typically specify limits to ensure safety and consistency; common specification targets include individual unspecified impurities not exceeding 0.10 percent weight by weight, any identified or specified impurity often limited to 0.20 percent, and the total of related substances generally limited to 0.50 percent, with tighter limits applied for genotoxic impurities if present. Process-related and degradation compounds that occur during synthesis or storage are characterized structurally and by toxicological qualification where required; residual solvents are controlled per ICH Q3C with Class 2 solvents restricted to allowed daily exposures and heavy metals are controlled per applicable pharmacopeial limits, while water content and assay are maintained within validated release and stability criteria.
Upadacitinib is used to treat a range of immune-mediated inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, and axial spondyloarthritis in accordance with approved indications and dosing guidelines.
Yes, upadacitinib is an immunomodulatory agent with immunosuppressive effects because it inhibits JAK1-mediated cytokine signaling, which can reduce immune responses and increase the risk of infections; appropriate screening and monitoring are recommended.
Cost varies by country, dose, pharmacy and insurance coverage; list prices in some markets can amount to several thousand dollars per month before insurance, so consult local suppliers, insurers or manufacturer assistance programs for current, location specific pricing.
Upadacitinib is a selective JAK1 inhibitor with higher selectivity for JAK1 over JAK2, JAK3 and TYK2, designed to preferentially block JAK1-dependent cytokine signaling pathways.
